Novartis Appoints Sloan Simpson as Global Head of Investor Relations

Novartis Appoints Sloan Simpson as Global Head of Investor Relations
angilma1

Listening to the CML patient community

Listening to the CML patient community
weberfr8

How collaboration can enhance your science career

How collaboration can enhance your science career
weberfr8

Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash

Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
arcticnovartis

  • Transaction to include pelabresib, a late-stage BET inhibitor for myelofibrosis (MF) and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or lymphomas
  • Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement with a well-tolerated safety profile in Phase 3 MANIFEST-2 study, when administered in combination with ruxolitinib in JAK inhibitor-naive MF patients1
Novartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III

Novartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III
arcticnovartis

Annonce événementielle au sens de l’art. 53 RC

Exercice complet (activités poursuivies2)

Starkes Jahresergebnis: Novartis steigert den Nettoumsatz um 10%, das operative Kernergebnis um 18% (kWk¹) sowie die Margen. Weitere Innovationsdynamik mit mehreren positiven Phase-3-Ergebnissen

Starkes Jahresergebnis: Novartis steigert den Nettoumsatz um 10%, das operative Kernergebnis um 18% (kWk¹) sowie die Margen. Weitere Innovationsdynamik mit mehreren positiven Phase-3-Ergebnissen
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR 

Geschäftsjahr (fortzuführende Geschäftsbereiche2)

Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts

Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

Full year (continuing operations2)

In Colombia, a researcher works against a devastating disease

In Colombia, a researcher works against a devastating disease
tavasat1

Going upstream to improve heart health in Philadelphia

Going upstream to improve heart health in Philadelphia
mihai_novartis

A cancer patient gets a new lease on life

A cancer patient gets a new lease on life
tavasat1